54533-84-5

Basic information

• Product Name: 2H-Pyran,2-[2-(2-chloroethoxy)ethoxy]tetrahydro
• Synonyms: 2H-Pyran,2-[2-(2-chloroethoxy)ethoxy]tetrahydro;2-[2-(2-chloroethoxy)ethoxy]oxane
• CAS NO: 54533-84-5
• Molecular Formula: C₉H₁₇ClO₃
• Molecular Weight: 208.68248
• Mol File: 54533-84-5.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2H-Pyran,2-[2-(2-chloroethoxy)ethoxy]tetrahydro(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Pyran,2-[2-(2-chloroethoxy)ethoxy]tetrahydro(54533-84-5)
• EPA Substance Registry System: 2H-Pyran,2-[2-(2-chloroethoxy)ethoxy]tetrahydro(54533-84-5)

Safety Data

• Hazardous Substances Data: 54533-84-5(Hazardous Substances Data)

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 628-89-7 2-(2-Chloroethoxy)ethanol 

Downstream Products

• 125365-35-7 Methyl 3,5,6-tri-O-benzyl-2-O-(2-tetrahydropyranyloxyethoxy)ethyl-β-<*>-glucofuranose 
• 253600-67-8 2-[2-(2-{4-[Tris-(4-tert-butyl-phenyl)-methyl]-phenoxy}-ethoxy)-ethoxy]-tetrahydro-pyran 
• 96574-06-0 14-(2-Methoxyphenoxy)-3,6,9,12-tetraoxa-1-tetradecanol 
• 88454-94-8 C₃₆H₅₄O₁₀ 
• 109774-75-6 C₅₇H₈₁N₃O₁₅S₃ 
• 123845-43-2 2-(4-Benzyloxy-1-methyl-1-{2-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-ethoxy}-butyl)-3-{2-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-ethoxymethyl}-benzo[1,4]dioxine 
• 74292-07-2 C₅₀H₄₄O₆*C₈H₉NO₂*ClHO₄ 
• 119318-83-1 C₄₀H₆₂O₈ 
• 119318-77-3 C₃₉H₆₀O₈ 
• 119319-09-4 C₃₅H₆₀O₈ 
• 98846-93-6 N,N,N-tris<8-(tetrahydro-2H-pyran-2-yl)oxy-3-tosyl-6-oxa-3-azaoctyl>amine 
• 119319-10-7 C₃₃H₅₆O₈ 
• 119319-07-2 C₃₂H₅₄O₈ 
• 124414-49-9 C₃₂H₄₆O₈ 

Relevant articles and documents

-

-

NOVEL AROMATIC COMPOUND AND USE THEREOF

Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or To treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.

SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.